

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Lynn Macdonald	01/19/2011
Naxin Tu	01/19/2011
Cagen Gurer	01/19/2011
Sean Stevens	12/19/2010
Andrew J. Murphy	01/19/2011
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	Regeneron Pharmaceuticals, Inc.
<b>Street Address:</b>	777 Old Saw Mill River Road
<b>City:</b>	Tarrytown
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10591-6707
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	12971080
Application Number:	61288562
PCT Number:	US1060925
<b>CORRESPONDENCE DATA</b>	
Fax Number:	(914)345-7705
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	914-593-1081
Email:	james.kang@regeneron.com
Correspondent Name:	James Kang
Address Line 1:	777 OLD SAW MILL RIVER ROAD
Address Line 4:	TARRYTOWN, NEW YORK 10591
ATTORNEY DOCKET NUMBER:	3070

CH \$120.00 12971080

**501409968**

**PATENT**  
**REEL: 025659 FRAME: 0398**

NAME OF SUBMITTER:

James Kang

Total Attachments: 2

source=3070A\_Assignment#page1.tif

source=3070A\_Assignment#page2.tif

## ASSIGNMENT

**WHEREAS**, I (WE), **Lynn MACDONALD**, a citizen of US, residing at 16 Gedney Way, White Plains, NY 10605, USA; **Naxin TU**, a citizen of China, residing at 514 Washington Avenue, Pleasantville, NY 10570, USA; **Cagan GURER**, a citizen of Turkey; residing at 8 Pamela Lane, Valhalla, NY 10595, USA; **Sean STEVENS**, a citizen of US, residing at 355 Berry Street, #413, San Francisco, CA 94158, USA; and, **Andrew J. MURPHY**, a citizen of US, residing at 10 Newton Court, Croton-on-Hudson, NY 10520, USA; (hereinafter called "ASSIGNOR(S)") am (are) inventor(s) of the invention(s) disclosed and/or claimed in the following patent applications:

**MICE LACKING ENDOGENOUS FC $\gamma$ R GENES AND MICE EXPRESSING HUMAN LOW AFFINITY Fc $\gamma$ Rs**

US Provisional Patent Application Serial No. 61/288,562, filed 21 December 2009

and

**HUMANIZED FC $\gamma$ R MICE**

US Nonprovisional Patent Application Serial No. 12/971,080, filed 17 December 2010

and

**HUMANIZED FC $\gamma$ R MICE**

PCT Int'l Application Serial No. PCT/US10/60925, filed 17 December 2010

**WHEREAS**, **REGENERON PHARMACEUTICALS INC.**, a corporation organized and existing under the laws of the State of New York, with offices at 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707, U.S.A. (hereinafter called "ASSIGNEE") is desirous of acquiring my (our) entire right, title and interest in, to, and under said application(s);

**NOW, THEREFORE**, in consideration of the sum of One Dollar (\$1.00) to me (us) in hand paid, and other good and valuable consideration, the receipt of which is hereby acknowledged, I (we), said ASSIGNOR(S), have sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over unto said ASSIGNEE, its successors, legal representatives, and assigns, my (we) entire right, title and interest for all countries in and to any and all inventions which are disclosed and claimed, and any and all inventions which are disclosed but not claimed, in the above-described United States application(s), and in and to said United States Application(s) and all divisions, renewals, continuations, and continuations-in-part thereof, and all Patents of the United States which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents utility models, and designs which may hereafter be filed for said inventions in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States application(s) under the Patent Laws of the United States, the International Convention of 1883 and later modifications thereof, under the Patent Cooperation Treaty, under the European Patent Convention, or under any other available international agreement or under the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which

may be granted for said inventions in any country or countries foreign to the United States and all extensions, renewals and reissues thereof;


**AND I (WE) HEREBY** authorize and request the Commissioner of Patents and Trademarks of the United States and any Official of any country or countries foreign to the United States whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the said ASSIGNEE, their successors, legal representatives and assigns, in accordance with this instrument;

**AND I (WE) HEREBY** covenant and agree that I (we) have full right to convey the entire interest hereinafter assigned, and that I (we) have not executed, and will not execute, any agreement in conflict herewith;


**AND I (WE) HEREBY** further covenant and agree that I (we) will communicate to said ASSIGNEE, its successors, legal representatives and assigns, any facts known to me (us) respecting said inventions, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, continuation-in-part, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid said ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper protection for said inventions in all countries.

**IN TESTIMONY WHEREOF**, I (we) hereunto set my (our) hand(s) and seal the day and year set opposite my (our) signature(s).


Dated: 1-19-2011

  
Lynn MACDONALD

Dated: 1-19-2011

  
Naxin TU


Dated: 1-19-2011

  
Cagan GURER

Dated: 12/19/10

  
Sean STEVENS

Dated: 1/19/11

  
Andrew J. MURPHY

END